Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sildenafil for Moderate to Severe Raynaud's Phenomenon
NCT02050360Phase 3Completed
- Sponsor
- CHU Grenoble Alpes
- Start
- Nov 2013
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sildenafil in Raynaud's phenomenon (RP), sponsored by CHU Grenoble Alpes. Started Nov 2013; status: completed.
02
Drugs
sildenafil
03
Conditions
Raynaud's phenomenon (RP)
Beyond the preview
Go deeper on NCT02050360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02050360.